JTTT SEC filings, in plain English
Everything JATT III Acquisition Corp has filed with the SEC that we hold — 13 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: JATT III Acquisition Corp filed an 8-K on September 2, 2026, confirming the consummation of its IPO on August 27, 2026, which sold 6,900,000 ordinary shares at $10.00 per share for $69,000,000 in gross proceeds, including the full exercise of the underwriters' over-allotment option. Simultaneously, the Company completed a private placement of 234,000 shares to JATT Ventures III L.P. for $2,340,000, resulting in a total of $69,000,000 deposited into the trust account as of August 27, 2026. Why it matters: This filing establishes the final capitalization and trust value ($10.00 per share) for public shareholders, defining the baseline for potential redemption values and the funds available for a future business combination search.
What changed: JATT III Acquisition Corp consummated its IPO on August 27, 2026, selling 6,900,000 ordinary shares at $10.00 per share for $69,000,000 in gross proceeds, and simultaneously sold 234,000 private placement shares to sponsor JATT Ventures III L.P. for $2,340,000. The filing appoints four independent directors (Verender S. Badial, Christopher Staral, Arjun Goyal, Jonathon Kluft) and establishes a trust account with net proceeds of $69,000,000, subject to redemption if a business combination is not completed within 24 months. Why it matters: This filing confirms the capital raise and initial governance structure, establishing the 24-month deadline by which investors must track deal progress or prepare for potential redemption of their $10 per share trust value.
What changed: S-1 registration statement for a $60 million (up to $69 million with over-allotment) SPAC initial public offering of 6,000,000 ordinary shares (up to 6,900,000) at $10.00 per share, with no warrants sold to the public. JATT III Acquisition Corp, a newly-formed blank check company, filed the initial S-1 for its IPO on August 7, 2026. The filing formally sets forth the offering terms: $10.00 per share, a 24-month deadline to complete a business combination (which may be extended with a shareholder vote), an initial trust of $60 million ($69 million with over-allotment), a 20% founder-share structure (sponsor paid ~$0.0145/share), and no public warrants. The sponsors have secured non-binding indications of interest for up to $45 million in PIPE financing from AI Biotechnology ($30 million) and Vianti Capital ($15 million) to close concurrently with a business combination. Why it matters: This is the foundational document for a new SPAC led by Dr. Someit Sidhu, a serial biotech/SPAC entrepreneur with a track record (JATT I closed with Zura Bio in 2023; JATT II has a pending deal with Talawar). The SPAC is targeting healthcare/life sciences. The non-binding PIPE commitments provide a capital-stack signal. The trust per-share is $10.00. The 24-month clock starts at IPO closing. The structure includes a 20% shareholder-redemption cap per group, a $10.00 per-share trust floor guaranteed by the sponsor, and standard lock-ups (180 days for founder shares, 30 days for private placement shares).
What changed: DRS — Draft registration statement on Form S-1 filed confidentially with the SEC on July 17, 2026. This is a preliminary prospectus for the initial public offering of JATT III Acquisition Corp, a blank-check company. Initial confidential filing of the registration statement. Establishes the terms of the IPO: 6,000,000 ordinary shares at $10.00 per share, aiming to raise $60,000,000 ($69,000,000 if over-allotment exercised). Investors do not receive warrants. The trust will hold $10.00 per share. The sponsor (JATT Ventures III L.P.) commits to purchase 300,000 private placement shares ($3,000,000) simultaneously. The completion window is 24 months from the closing of the offering, with no mandatory redemption threshold. Redemption rights exist, but shareholders holding more than 20% of the shares are restricted from redeeming if the company seeks a shareholder vote. The filing also details the management team, conflicts of interest and prior SPAC experience, including JATT I (Zura Bio) and JATT II (Talawar Tx). Why it matters: This is the foundational filing for a new SPAC IPO. It confirms the terms investors will face. The trust is $10.00, but the redemption mechanics and the 20% redemption cap are significant structural features for tracking. The document underscores heavy dilution potential (sponsor paid $0.0145 per founder share) and outlines sponsor/management incentives to complete a deal. The focus on healthcare/biotech/life sciences is stated. The lack of a specified maximum redemption threshold and the quorum voting dynamics could allow a deal to close with minimal public shareholder support.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.